Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.70 |
| ▸ | ANPEP | P15144 | 3/20 | 0.70 |
| ▸ | DNPEP | Q9ULA0 | 3/20 | 0.70 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.70 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679505 | 1.00 | LAP3 (0.70) | LAP3ANPEPDNPEPRNPEPREN | |
| SCHEMBL4071253 | 0.91 | CYP3A4 (0.56) | LAP3ANPEPDNPEPRNPEPREN | |
| SCHEMBL12609439 | 0.82 | LAP3 (1.00) | LAP3ANPEPDNPEPRNPEPREN | |
| SCHEMBL6832228 | 0.79 | CCR1 (0.54) | LAP3ANPEPDNPEPRNPEPCCR1 | |
| SCHEMBL7580246 | 0.79 | CCR1 (0.54) | LAP3ANPEPDNPEPRNPEPCCR1 | |
| SCHEMBL3210913 | 0.78 | ANPEP (0.74) | LAP3ANPEPDNPEPRNPEPL3MBTL1 | |
| SCHEMBL7299909 | 0.78 | ANPEP (0.74) | LAP3ANPEPDNPEPRNPEPL3MBTL1 | |
| SCHEMBL3210919 | 0.78 | ANPEP (0.74) | LAP3ANPEPDNPEPRNPEPL3MBTL1 | |
| SCHEMBL4043571 | 0.76 | REN (0.63) | LAP3ANPEPDNPEPRNPEPREN | |
| SCHEMBL4068036 | 0.76 | REN (0.62) | LAP3RENCCR1ERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | LAP3 3585/4885ANPEP 4623/4885DNPEP 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.